CN102008504A - Blood plasma product for clinical transfusion and preparation method thereof - Google Patents
Blood plasma product for clinical transfusion and preparation method thereof Download PDFInfo
- Publication number
- CN102008504A CN102008504A CN2010105777009A CN201010577700A CN102008504A CN 102008504 A CN102008504 A CN 102008504A CN 2010105777009 A CN2010105777009 A CN 2010105777009A CN 201010577700 A CN201010577700 A CN 201010577700A CN 102008504 A CN102008504 A CN 102008504A
- Authority
- CN
- China
- Prior art keywords
- blood
- blood plasma
- transfusion
- cord
- clinical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002381 plasma Anatomy 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims abstract description 39
- 239000008280 blood Substances 0.000 claims abstract description 39
- 210000004700 fetal blood Anatomy 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 208000032467 Aplastic anaemia Diseases 0.000 claims abstract description 6
- 244000000010 microbial pathogen Species 0.000 claims abstract description 4
- 239000003223 protective agent Substances 0.000 claims abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 230000002924 anti-infective effect Effects 0.000 claims description 5
- 230000002607 hemopoietic effect Effects 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 210000003954 umbilical cord Anatomy 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 210000003677 hemocyte Anatomy 0.000 claims description 3
- 229940000351 hemocyte Drugs 0.000 claims description 3
- 210000002826 placenta Anatomy 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 210000000601 blood cell Anatomy 0.000 abstract description 2
- 230000011132 hemopoiesis Effects 0.000 abstract description 2
- 208000035010 Term birth Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 238000001802 infusion Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 230000002281 colonystimulating effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a blood plasma product for clinical transfusion and a preparation method thereof. The blood plasma product is prepared from cord blood. The preparation method is as follows: the cord blood in placeta umbilic, which is wasted from a term birth infant, is collected and is centrifuged, and nucleated cells are removed; ABO and Rh blood type detection, blood cell and blood plasma component measurement, pathogenic microorganism immunoassay and germiculture are carried out on the obtained blood plasma without the nucleated cells; and qualified blood plasma is detected, a proper amount of protective agent is added, spin-freeze is carried out at the temperature of minus 35 DEG C for 2 hours, and then freeze-drying is carried out at the temperature of 35 DEG C-37 DEG C within 18-20 hours to obtain the freeze-dried cord blood plasma product. The transfusion comprises common clinical transfusion and transfusion in the aspects of malignant tumor subject to chemo-treatment/radiation treatment and poor hematopoiesis diseases caused by aplastic anemia. The cord blood is a special transfusion resource with important treatment function and also a source of important candidate stem cells.
Description
Technical field
The present invention relates to a kind of blood plasma product and preparation method thereof, especially a kind of derive from Cord blood be used for blood plasma product of clinical blood transfusion and preparation method thereof.
Background technology
As everyone knows, blood is to save the indispensable material of some critical patient's life.The work of China's voluntary blood donation has in recent years obtained remarkable progress, but in general, breach is still very big between China's blood demand and the supply, nearly 1000 tons of annual blood using amount, and voluntary blood donation can only be satisfied the blood using amount less than 30%.Being in an emergency and happening occasionally in the blood source, still needs import to meet clinical needs.
Cord blood is to residue in umbilical cord and intraplacental blood behind the disconnected umbilicus of neonate birth.Oneself becomes a kind of important hematopoietic stem cell source that is used for clinical transplantation Cord blood.Because wherein competent cell and molecule composition are higher than adult's blood or for the blood of being grown up is not had, in recent years the Cord blood infusion after malignant tumorization/radiotherapy and the aspects such as Supporting Therapy of the short hemopoietic treatment of HD disease such as aplastic anemia, anti-infective therapy, immunization therapy, serious disease obtained challenging effect.
Summary of the invention
Technical problem to be solved by this invention is, provide a kind of derive from Cord blood be used for blood plasma product of clinical blood transfusion and preparation method thereof.
In order to solve the problems of the technologies described above, the technical solution used in the present invention is: a kind of blood plasma product that is used for clinical blood transfusion, it is prepared by Cord blood.
The described preparation method that is used for the blood plasma product of clinical blood transfusion comprises the steps:
(1) Cord blood of the depleted Placenta Hominis umbilical cord of collection term labor baby is centrifugal, removes nucleated cell;
(2) go gained blood plasma to carry out ABO and the detection of Rh blood group, hemocyte and blood plasma components mensuration, pathogenic microorganism immune detection and antibacterial culturing;
(3) detect qualified blood plasma, add an amount of protective agent, revolve under-35 ℃ and freeze, after 2 hours, under 35 ℃-37 ℃, cold dry-cure in the 18-20 hour, obtain lyophilizing Cord blood slurry formulation.
After described blood transfusion comprises common clinical blood transfusion and is used for malignant tumorization/radiotherapy and the blood transfusion of the Supporting Therapy aspect of the short hemopoietic treatment of aplastic anemia HD disease, anti-infective therapy, immunization therapy, serious disease.
The invention has the beneficial effects as follows: Cord blood also is a kind of special blood resource with critical treatment effect except being a kind of important hematopoietic stem cell source, and it is with a wide range of applications in clinical.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is described in further detail:
The blood plasma product that is used for clinical blood transfusion of the present invention, it is prepared by Cord blood.
The described preparation method that is used for the blood plasma product of clinical blood transfusion comprises the steps:
(1) Cord blood of the depleted Placenta Hominis umbilical cord of collection term labor baby is centrifugal, removes nucleated cell;
(2) go gained blood plasma to carry out ABO and the detection of Rh blood group, hemocyte and blood plasma components mensuration, pathogenic microorganism immune detection and antibacterial culturing;
(3) detect qualified blood plasma, add an amount of protective agent, revolve under-35 ℃ and freeze, after 2 hours, under 35 ℃-37 ℃, cold dry-cure in the 18-20 hour, obtain lyophilizing Cord blood slurry formulation.
After described blood transfusion comprises common clinical blood transfusion and is used for malignant tumorization/radiotherapy and the blood transfusion of the Supporting Therapy aspect of the short hemopoietic treatment of aplastic anemia HD disease, anti-infective therapy, immunization therapy, serious disease.
Cord blood cell is longer than the adult blood cell survival, and various hemopoietic growth factors are several times of normal level even higher in the cord blood plasma, and the Cord blood infusion can stimulate normal hematopoiesis.Cord blood infusion obviously ameliorate tumor is put/bone marrow depression degree after the chemotherapy, reduce the bone marrow depression phase, thereby reduce complication, improve overall survival rate, and cord blood plasma can inducing leukemia cell enter proliferating cycle, strengthen the sensitivity of leukaemia to chemotherapy.Chemotherapy combined Cord blood infusion can improve leukemic remission rate.
Chronic aplastic anemia (CAA) patient gives can obviously improve its peripheral hemogram behind the Cord blood infusion, the myeloid progenitor level that raises rapidly, and blood plasma colony stimulating activity and quick-fried formula colony stimulating activity that pathologic is raise recover normal.Cord blood infusion and Drug therapy are united CAA are had cooperative effect, can reduce drug dose and shorten the course of treatment, and can reduce the dependence to blood transfusion.
Contain multiple micromolecule polypeptide in the cord blood plasma, have immunostimulant and immunoregulation effect, can increase total complement level in the serum, promote the phagocyte phagocytosis, improve the human peripheral blood leucocyte level.Contain a large amount of immunoglobulins in the umbilical blood, therefore, it has very strong immunocompetence.Content of hemoglobin height in the umbilical blood has affinity highly to oxygen, helps improving anoxia and the related symptoms that anemia causes.Umbilical blood and cord blood plasma infusion have good Supporting Therapy and non-specific wide spectrum anti-infectious function, help strengthening the physical function and the resistance of patient with severe symptoms and infected patient, promote the control of disease.
Therefore, Cord blood except be-kind of important hematopoietic stem cell source, also be a kind of special blood resource with critical treatment effect, it is with a wide range of applications in clinical.
In sum, content of the present invention is not limited in the above-described embodiment, and the knowledgeable people in the same area can propose other embodiment easily within technological guidance's thought of the present invention, but this embodiment comprises within the scope of the present invention.
Claims (3)
1. a blood plasma product that is used for clinical blood transfusion is characterized in that, it is prepared by Cord blood.
2. be used for the preparation method of the blood plasma product of clinical blood transfusion according to claim 1, it is characterized in that, comprise the steps:
(1) Cord blood of the depleted Placenta Hominis umbilical cord of collection term labor baby is centrifugal, removes nucleated cell;
(2) go gained blood plasma to carry out ABO and the detection of Rh blood group, hemocyte and blood plasma components mensuration, pathogenic microorganism immune detection and antibacterial culturing;
(3) detect qualified blood plasma, add an amount of protective agent, revolve under-35 ℃ and freeze, after 2 hours, under 35 ℃-37 ℃, cold dry-cure in the 18-20 hour, obtain lyophilizing Cord blood slurry formulation.
3. the blood plasma product that is used for clinical blood transfusion according to claim 1, it is characterized in that, after described blood transfusion comprises common clinical blood transfusion and is used for malignant tumorization/radiotherapy and the blood transfusion of the Supporting Therapy aspect of the short hemopoietic treatment of aplastic anemia HD disease, anti-infective therapy, immunization therapy, serious disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105777009A CN102008504A (en) | 2010-12-09 | 2010-12-09 | Blood plasma product for clinical transfusion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105777009A CN102008504A (en) | 2010-12-09 | 2010-12-09 | Blood plasma product for clinical transfusion and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102008504A true CN102008504A (en) | 2011-04-13 |
Family
ID=43838966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105777009A Pending CN102008504A (en) | 2010-12-09 | 2010-12-09 | Blood plasma product for clinical transfusion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102008504A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102250838A (en) * | 2011-06-04 | 2011-11-23 | 内蒙古医学院 | Clinical and experimental foreign protein-free stem cell culture medium additive and application thereof |
| CN109679889A (en) * | 2018-12-28 | 2019-04-26 | 英科博雅生命科技有限公司 | The preparation method of cord blood plasma Essence or its freeze dried powder |
| JP2019523281A (en) * | 2016-08-01 | 2019-08-22 | エンブリオジェネシス ピーティーワイ リミテッド | Skin care formulation |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
-
2010
- 2010-12-09 CN CN2010105777009A patent/CN102008504A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102250838A (en) * | 2011-06-04 | 2011-11-23 | 内蒙古医学院 | Clinical and experimental foreign protein-free stem cell culture medium additive and application thereof |
| CN102250838B (en) * | 2011-06-04 | 2014-03-19 | 内蒙古医学院 | Clinical and experimental foreign protein-free stem cell culture medium additive and application thereof |
| JP2019523281A (en) * | 2016-08-01 | 2019-08-22 | エンブリオジェネシス ピーティーワイ リミテッド | Skin care formulation |
| US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| CN109679889A (en) * | 2018-12-28 | 2019-04-26 | 英科博雅生命科技有限公司 | The preparation method of cord blood plasma Essence or its freeze dried powder |
| CN109679889B (en) * | 2018-12-28 | 2022-06-24 | 英科博雅生命科技有限公司 | Preparation method of cord blood plasma essence or freeze-dried powder thereof |
| US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
| US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| US11994343B2 (en) | 2019-03-14 | 2024-05-28 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11986553B2 (en) | Multi-component injection | |
| CN102008504A (en) | Blood plasma product for clinical transfusion and preparation method thereof | |
| Li et al. | Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma | |
| CN104666344A (en) | Application of MSC (mesenchymal stem cell) exosomes in preparation of pharmaceutic preparation for treating PF (pulmonary fibrosis) | |
| Smith-Berdan et al. | Dynamic expression of the Robo ligand Slit2 in bone marrow cell populations | |
| EP3551178A1 (en) | Markers for personalized cancer treatment with lsd1 inhibitors | |
| CN102973922B (en) | A kind of application of fusion rotein | |
| CN114085812A (en) | Mesenchymal stem cell population with high expression of CD106 and/or CD142 and reduced expression, and preparation method and application thereof | |
| Dong et al. | Autologous dendritic cells combined with cytokine-induced killer cells synergize low-dose chemotherapy in elderly patients with acute myeloid leukaemia | |
| Chen et al. | Role of the immune system in liver transplantation and its implications for therapeutic interventions | |
| Arfianti et al. | Hipoxia modulates the secretion of growth factors of human umbilical cord-derived mesenchymal stem cells | |
| CN103013914B (en) | Method for in-vitro culture of killer T cells | |
| CN111374975A (en) | Medicinal application of harmine | |
| Zheng et al. | Effects of extracellular vesicles derived from mesenchymal stem/stromal cells on liver diseases | |
| CN101914497A (en) | Clinical N-CIK cell culture and quality control and identification kit and application | |
| Kuang et al. | Expert consensus on the application of stem cells in psoriasis research and clinical trials | |
| CN102106864A (en) | Application of icariin for preparing medicament for resisting myeloid-derived suppressor cells (MDSCs) | |
| Nio et al. | Cytotoxic and cytostatic effects of the streptococcal preparation OK‐432 and its subcellular fractions on human ovarian tumor cells | |
| CN113577070A (en) | Combined pharmaceutical composition for treating acute myeloid leukemia and application thereof | |
| Takami et al. | Novel findings for the development of drug therapy for various liver diseases: Current state and future prospects for our liver regeneration therapy using autologous bone marrow cells for decompensated liver cirrhosis patients | |
| CN108753719B (en) | A method of the LAK LAK of derived from cord blood is improved to tumor-killing power | |
| Chen et al. | Combination of Cobe AutoPBSC and Gambro Elutra as a platform for monocyte enrichment in dendritic cell (DC) therapy: clinical study | |
| CN1418633A (en) | Anti-cancer assistant medicine contg. 20(S)-protopanaxadiol as effective component, and its application | |
| CN1264506C (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
| CN109602745B (en) | Application of 2-indolecarboxamide compounds in the preparation of anticancer drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110413 |